In the News
>> Sunovion Pharmaceuticals Inc. and Afraxis, Inc. Announce Novel Drug Discovery Partnership
August 13, 2013
Sunovion Pharmaceuticals Inc. (Sunovion) and Afraxis, Inc. today announced that they have signed a partnership agreement to utilize the unique Enhanced Spine Platform (ESP) developed by Afraxis, Inc. to accelerate Sunovion?s preclinical central nervous system (CNS) drug discovery process.

>> Technology to Asses Neurons Gives New Life To San Diego's Afraxis
August 19, 2013
San Diego's Afraxis, wgich ceased to exist in January, has sprung back to life with proprietary technology that was not part of the 187.5 million dollar deal.

Underlying Science
A brain's neural network is made up of specialized cells called neurons that are interconnected at points called synapses.
Read More > >

"The brain is a world consisting of numerous unexplored continents and great expanses of unknown territory." - Santiago Ramon y Cajal (1906 Nobel Prize in Physiology or Medicine)

Disorders of the Central Nervous System (CNS) - such as schizophrenia, Alzheimer's disease, Fragile X Syndrome and Autism Spectrum Disorders - affect millions of people. These disorders can be devastating for the sufferers, as well as their families and caregivers. Unfortunately, there are often no treatment options to address the symptoms of these disorders. Despite billions of dollars of efforts by the pharmaceutical industry and government-funded research, there are relatively few viable drug development candidates for these CNS disorders. This is owed largely to the extreme difficulties in understanding even the most basic principles of how the brain processes and stores information across its complex and vast networks. It is widely agreed that what is critically needed is a road map to the brain's information processing system.

Afraxis Inc. develops technologies to facilitate the discovery and development of novel CNS therapeutics. At its core is the Afraxis Enhanced Spine Platform (ESP) technology, which reads and interprets the fundamental building block of biological neural networks - the synapse. Afraxis ESP is the first of its kind, a high-content drug discovery tool to measure the conformations of vast numbers of individual dendritic spines, the synapse's structural vessel. These conformations describe information processing "fingerprints", network growth and retraction in response to disease or therapeutics, and much more.

Armed with Afraxis ESP, CNS drug development is beginning to shape up... Read more

© Copyright 2013 Afraxis. Site design and layout by BFW Interactive          Home About Us Science ESP Platform Business Development Contact Us